Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature

Bibliography

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders text revision: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000
   Google Scholar
• Stein MB, Roy-Byrne PP, Craske MG, Functional impact and health utility if anxiety disorders in primary care outpatients. Med Care 2005;43:1164-70
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27
   PubMed Web of Science ®Google Scholar
• Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005;15:445-52
   PubMed Web of Science ®Google Scholar
• Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry 2005;66:22-9
   PubMed Web of Science ®Google Scholar
• McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain 2003;106:127-33
   PubMed Web of Science ®Google Scholar
• Kessler RC, McGonagle KA, Zhao S, Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
   PubMed Web of Science ®Google Scholar
• Feske U, Frank E, Mallinger AG, Anxiety as a correlate of response to acute treatment of bipolar I disorder. Am J Psychiatry 2000;157:956-62
   PubMed Web of Science ®Google Scholar
• Coryell W, Endicott J, Andreasen NC, Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. Am J Psychiatry 1988;145:293-300
   PubMed Web of Science ®Google Scholar
• Hettema JM, Kuhn JW, Prescott CA, Kendler KS. The impact of generalized anxiety disorder and stressful life events on risk for major depressive episodes. Psychol Med 2006;36:789-95
   PubMed Web of Science ®Google Scholar
• Bair MJ, Wu J, Damush TM, Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosom Med 2008;70:890-7
   PubMed Web of Science ®Google Scholar
• Kroenke K, Bair MJ, Damush TM, Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA 2009;301:2099-110
   PubMed Web of Science ®Google Scholar
• Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry 2005;66:22-9
   PubMed Web of Science ®Google Scholar
• Stahl SM. The psychopharmacology of painful physical symptoms in depression. J Clin Psychiatry 2002;63:382-3
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99
   PubMed Web of Science ®Google Scholar
• Perahia DG, Quail D, Desaiah D, Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res 2009;43:512-18
   PubMed Web of Science ®Google Scholar
• Wong DT, Bymaster FP, Mayle DA, LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1993;8:23-33
   PubMed Web of Science ®Google Scholar
• Lantz RJ, Gillespie TA, Rash TJ, Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003;31:1142-50
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropsychopharmacology 2001;25:871-80
   PubMed Web of Science ®Google Scholar
• Gupta S, Nihalani N. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. Ann Clin Psychiatry 2007;19:125-32
   PubMedGoogle Scholar
• Bymaster FP, Beedle EE, Findlay J, Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett 2003;13:4477-80
   PubMed Web of Science ®Google Scholar
• Skinner MH, Kuan HY, Skerjanec A, Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharmacol 2004;57:54-61
   PubMed Web of Science ®Google Scholar
• Skinner MH, Skerjanec A, Seger M, The effect of food and bedtime administration on duloxetine pharmacokinetics [abstract no. PII-59]. Clin Pharmacol Ther 2000;67:129
   Web of Science ®Google Scholar
• Whitmyer VG, Dunner DL, Kornstein SG, A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry 2007;68:1921-30
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Cymbalta® (duloxetine hydrochloride) delayed-release capsules for oral use: Highlights of US prescribing information [online]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021427s029lbl.pdf [Last accessed 8 February 2010]
   Google Scholar
• Wells KA, Losin WG. In vitro stability, potency, and dissolution of duloxetine enteric-coated pellets after exposure to applesauce, apple juice, and chocolate pudding. Clin Ther 2008;30:1300-8
   PubMed Web of Science ®Google Scholar
• Cymbalta 30 mg hard gastro-resistant capsules, Cymbalta 60 mg hard gastro-resistant capsules, Summary of Product Characteristics, 2009. Available from: http://emc.medicines.org.uk/medicine/15694/SPC/Cymbalta+30mg+hard+gastro-resistant+capsules,+Cymbalta+60mg+hard+ gastro-resistant+capsules/#INTERACTIONS#ixzz0JTKT47Xj&D [Last accessed 1 September 2009]
   Google Scholar
• Wrase J, Reimold M, Puls I, Serotonergic dysfunction: brain imaging and behavioral correlates. Cogn Affect Behav Neurosci 2006;6:53-61
   PubMed Web of Science ®Google Scholar
• Schreiber R, Melon C, De Vry J. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology (Berl) 1998;135:383-91
   PubMed Web of Science ®Google Scholar
• Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000;12:2-19
   PubMed Web of Science ®Google Scholar
• Feldman S, Weidenfeld J. The excitatory effects of the amygdala on hypothalamo-pituitary-adrenocortical responses are mediated by hypothalamic norepinephrine, serotonin, and CRF-41. Brain Res Bull 1998;45:389-93
   PubMed Web of Science ®Google Scholar
• Goddard AW, Ball SG, Martinez J, Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress Anxiety 2009. [Epub ahead of print]
   Google Scholar
• Silverstone PH. Qualitative review of SNRIs in anxiety. J Clin Psychiatry 2004;65:19-28
   PubMed Web of Science ®Google Scholar
• Troelsen KB, Nielsen EØ, Mirza NR. Chronic treatment with duloxetine is necessary for anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology (Berl) 2005;181:741-50
   PubMed Web of Science ®Google Scholar
• Müller N, Schennach R, Riedel M, Möller HJ. Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Rev Neurother 2008;8:527-36
   PubMedGoogle Scholar
• Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ. Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety 2005;21:170-7
   PubMed Web of Science ®Google Scholar
• Thase ME, Pritchett YL, Ossanna MJ, Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007;27:672-6
   PubMed Web of Science ®Google Scholar
• Perahia DG, Maina G, Thase ME, Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:706-16
   PubMed Web of Science ®Google Scholar
• Nelson JC. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Depress Anxiety 2010;27:12-8
   PubMed Web of Science ®Google Scholar
• Dunner DL, Goldstein DJ, Mallinckrodt C, Duloxetine in the treatment of anxiety symptoms associated with depression. Depress Anxiety 2003;18:53-61
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-90
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-31
   PubMed Web of Science ®Google Scholar
• Fava M, Martinez JM, Greist J, The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry 2007;19:187-95
   PubMedGoogle Scholar
• Joffe H, Soares CN, Petrillo LF, Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry 2007;68:943-50
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Russell JM, Spann ME, Duloxetine in the treatment of generalized anxiety disorder. Expert Rev Neurother 2009;9:155-65
   PubMed Web of Science ®Google Scholar
• Koponen H, Allgulander C, Erickson J, Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007;9:100-7
   PubMedGoogle Scholar
• Rynn M, Russell J, Erickson J, Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008;25:182-9
   PubMed Web of Science ®Google Scholar
• Hartford J, Kornstein S, Liebowitz M, Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007;22:167-74
   PubMed Web of Science ®Google Scholar
• Nicolini H, Bakish D, Duenas H, Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 2009;39:267-76
   PubMed Web of Science ®Google Scholar
• Davidson JR, Wittchen HU, Llorca PM, Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2008;18:673-81
   PubMed Web of Science ®Google Scholar
• Perahia DG, Pritchett YL, Desaiah D, Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 2006;21:311-17
   PubMed Web of Science ®Google Scholar
• Raskin J, Wiltse CG, Siegal A, Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-9
   PubMed Web of Science ®Google Scholar
• Crippa JA, Filho AS, Freitas MC, Zuardi AW. Duloxetine in the treatment of social anxiety disorder. J Clin Psychopharmacol 2007;27(3):310
   PubMed Web of Science ®Google Scholar
• Choy Y, Fyer AJ, Lipsitz J. New and recent drugs for anxiety disorders. Prim Psychiatry 2007;15:50-6
   Google Scholar
• Nakatani E, Nakagawa A, Nakao T, A randomized controlled trial of Japanese patients with obsessive-compulsive disorder – effectiveness of behavior therapy and fluvoxamine. Psychother Psychosom 2005;74:269-76
   PubMed Web of Science ®Google Scholar
• Randhawa RS. A review of the pharmacotheraphy of obsessive-compulsive disorder and schizophrenia: the case of Sam. Cogn Behav Pract 2005;12:395-402
   Web of Science ®Google Scholar
• Dell’Osso B, Mundo E, Marazziti D, Altamura AC. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol 2008;22:210-13
   PubMed Web of Science ®Google Scholar
• Vieweg WV, Julius DA, Fernandez A, Posttraumatic stress disorder: clinical features, pathophysiology, and treatment. Am J Med 2006;119:383-90
   PubMed Web of Science ®Google Scholar
• Deneys ML, Ahearn EP. Exacerbation of PTSD symptoms with use of duloxetine. J Clin Psychiatry 2006;67:496-7
   PubMed Web of Science ®Google Scholar
• Hanretta AT, Malek-Ahmadi P. Combined use of ECT with duloxetine and olanzapine: a case report. J ECT 2006;22:139-41
   PubMed Web of Science ®Google Scholar
• Simon NM, Kaufman RE, Hoge EA, Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci Ther 2009;15:19-23
   PubMed Web of Science ®Google Scholar
• Crippa JA, Zuardi AW. Duloxetine in the treatment of panic disorder. Int J Neuropsychopharmacol 2006;9:633-4
   PubMedGoogle Scholar
• Endicott J, Russell JM, Raskin J, Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J Clin Psychiatry 2007;68:518-24
   PubMed Web of Science ®Google Scholar
• Cramer V, Torgersen S, Kringlen E. Quality of life and anxiety disorders: a population study. J Nerv Ment Dis 2005;193:196-202
   PubMed Web of Science ®Google Scholar
• Stein MB, Roy-Byrne PP, Craske MG, Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care 2005;43:1164-70
   PubMed Web of Science ®Google Scholar
• Pollack MH, Endicott J, Liebowitz M, Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res 2008;42:1042-9
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Meyers AL, Prakash A, The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Curr Med Res Opin 2008;24:2457-66
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Lee TC, Knadler MP, The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 2005;11:1475-93
   PubMed Web of Science ®Google Scholar
• Greist J, McNamara RK, Mallinckrodt CH, Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004;26:1446-55
   PubMed Web of Science ®Google Scholar
• Davidson J, Allgulander C, Pollack MH, Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol 2008;23:519-26
   PubMed Web of Science ®Google Scholar
• Wernicke J, Lledó A, Raskin J, An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007;30:437-55
   PubMed Web of Science ®Google Scholar
• Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin psychopharmacol 1988;8:323-30
   PubMed Web of Science ®Google Scholar
• Wise TN, Perahia DG, Pangallo BA, Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry 2006;8:269-78
   PubMedGoogle Scholar
• Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 2001;62(Suppl 3):22-34
   PubMedGoogle Scholar
• Clayton AH, Balon R. The impact of mental illness and psychotropic medications on sexual functioning: the evidence and management. J Sex Med 2009;6:1200-11
   PubMed Web of Science ®Google Scholar
• Delgado PL, Brannan SK, Mallinckrodt CH, Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66:686-92
   PubMed Web of Science ®Google Scholar
• Clayton A, Kornstein S, Prakash A, Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007;4:917-29
   PubMed Web of Science ®Google Scholar
• Wernicke J, Pangallo B, Wang F, Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf 2008a;3:132-42
   PubMedGoogle Scholar
• Khan AY, Macaluso M. Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat 2009;5:23-31
   PubMed Web of Science ®Google Scholar
• Menchetti M, Gozzi BF, Saracino MA, Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines. World J Biol Psychiatry 2009;10:385-9
   PubMed Web of Science ®Google Scholar
• Zhu B, Zhao Z, Ye W, The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder. J Nerv Ment Dis 2009;197:136-9
   PubMed Web of Science ®Google Scholar
• Katzman MA. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs 2009;23:103-20
   PubMed Web of Science ®Google Scholar
• Barkin RL, Barkin S. The role of velafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Ther 2005;12:431-8
   PubMedGoogle Scholar
• Harmer CJ, Hill SA, Taylor MJ, Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am J Psychiatry 2003;160:990-2
   PubMed Web of Science ®Google Scholar
• Herrera-Guzmán I, Gudayol-Ferré E, Herrera-Guzmán D, Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatry Res 2009;43:855-63
   PubMed Web of Science ®Google Scholar
• Russell JM, Weisberg R, Fava M, Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety 2008;25:E1-11
   PubMed Web of Science ®Google Scholar